MedPath

Shenzhen Kexing Pharmaceutical Co., Ltd.

🇨🇳China
Ownership
Private, Subsidiary
Established
2018-03-23
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:0
Completed:2

Trial Phases

4 Phases

Phase 1:1
Phase 2:1
Phase 3:1
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Not Applicable
1 (25.0%)
Phase 1
1 (25.0%)
Phase 2
1 (25.0%)
Phase 3
1 (25.0%)

Evaluating the Efficacy and Safety of GB08 Injection in Pediatric Patients With Growth Hormone Deficiency

Not Applicable
Not yet recruiting
Conditions
Growth Hormone Deficiency in Children
Growth Hormone Deficiency (GHD)
Growth Hormone
Interventions
First Posted Date
2025-08-17
Last Posted Date
2025-08-22
Lead Sponsor
Shenzhen Kexing Pharmaceutical Co., Ltd.
Target Recruit Count
268
Registration Number
NCT07126288
Locations
🇨🇳

Xiamen Maternal and Child Health Hospital, Xiamen, Fujian, China

🇨🇳

Nanyang Central Hospital, Nanyang, Henan, China

🇨🇳

The First Affiliated Hospital of Nanyang Medical College, Nanyang, Henan, China

and more 13 locations

Study Evaluating SHEN26 Capsule in Patients With Mild to Moderate COVID-19

Phase 3
Recruiting
Conditions
COVID-19
Interventions
Drug: SHEN26 capsule
Drug: SHEN26 placebo
First Posted Date
2023-06-18
Last Posted Date
2023-06-22
Lead Sponsor
Shenzhen Kexing Pharmaceutical Co., Ltd.
Target Recruit Count
1200
Registration Number
NCT05908071
Locations
🇨🇳

The First Affiliated Hospital Of Guangzhou Medical University, Guangzhou, Guangdong, China

Study of SHEN26 Capsule in Patients With Mild to Moderate COVID-19

Phase 2
Completed
Conditions
COVID-19
Interventions
Drug: SHEN26 dose 2
Drug: SHEN26 dose 1
Drug: SHEN26 placebo
First Posted Date
2023-01-09
Last Posted Date
2023-06-18
Lead Sponsor
Shenzhen Kexing Pharmaceutical Co., Ltd.
Target Recruit Count
91
Registration Number
NCT05676073
Locations
🇨🇳

Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China

🇨🇳

The Third People's Hospital of Shenzhen, Shenzhen, Guangdong, China

🇨🇳

Shenzhen Longhua District People's Hospital, Shenzhen, Guangdong, China

and more 1 locations

A Phase I Study of SHEN26 Capsule in Healthy Participants

Phase 1
Completed
Conditions
Healthy Participants
Interventions
Drug: SHEN26 capsule
Drug: SHEN26 placebo
First Posted Date
2022-08-17
Last Posted Date
2022-12-16
Lead Sponsor
Shenzhen Kexing Pharmaceutical Co., Ltd.
Target Recruit Count
86
Registration Number
NCT05504746
Locations
🇨🇳

The Second Hospital of Anhui Medical University, Hefei, Anhui, China

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.